Research Focus

PCCTC Operations; Project Manager

Recent additions – View all

1. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)

   Journal Article

   Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
   British Journal of Cancer (2024)

   Fulltext@MSK | Save
2. SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)

   Meeting Abstract

   Rathkopf, D. E.; Decker, B.; Schum, P.; McBride, S.
   Annals of Oncology (2021)

   Fulltext@MSK | Save
3. A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)

   Meeting Abstract

   Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
   Annals of Oncology (2021)

   Fulltext@MSK | Save